SCIENTIFIC JOURNAL of the Hungarian Society of Cardiology

The year in cardiovascular medicine 2022: the top 10 papers in heart failure and cardiomyopathies

█ Current opinion

DOI: 10.1093/eurheartj/ehac781

Rudolf A. de Boer1, Johann Bauersachs2
1Department of Cardiology, Erasmus MC, Dr. Molewaterplein 40, 3015GD Rotterdam, The Netherlands
2Department of Cardiology and Angiology, Hannover Medical School, Carl-Neuberg-Strasse 1,
D-30625 Hannover, Germany
Corresponding author:
Rudolf A. de Boer, MD, Tel: +31 10 703 3938, Fax: +31 (0) 10 7035498, E-mail:


The year of 2022 has been an exciting year in heart failure (HF). In this brief report, we will highlight some of the most provocative and impactful papers in the field.
Sodium–glucose co-transporter 2 (SGLT2) inhibitors are becoming one of the main treatments for patients with cardiorenal disease. Some uncertainties remained, e.g. if SGLT2 inhibitors were effective in patients with acute HF (AHF), or in HF with a left ventricular ejection fraction (LVEF) >40%, or in patients with improved LVEF. The Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure (EMPULSE; NCT04157751) trial enrolled 530 patients with acute de novo or decompensated HF to receive empagliflozin 10 mg once daily or placebo (1). The unique aspect of EMPULSE was that patients were randomized in hospital, when clinically stabilized (median time to randomization: 3 days), and were treated for up to 90 days. More patients treated with empagliflozin had clinical benefits compared with placebo (this was assessed by a ‘win’ ratio). Mortality and HF readmissions were also reduced.


click here to read the full article

click here to read the pdf